Roger Alistair Barker

Roger Alistair Barker's AcademicInfluence.com Rankings

Biology

#4753

World Rank

#7051

Historical Rank

Bioinformatics

#47

World Rank

#47

Historical Rank

Computational Biology

#66

World Rank

#66

Historical Rank

biology Degrees

Download Badge

Biology

Roger Alistair Barker's Degrees

Bachelors Biochemistry University of Oxford

Why Is Roger Alistair Barker Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roger Alistair Barker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

RNA velocity of single cells (2018) (1934)
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines (2012) (1851)
A Functional Role for Adult Hippocampal Neurogenesis in Spatial Pattern Separation (2009) (1523)
Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. (2001) (895)
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. (2007) (879)
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. (2009) (837)
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease (2010) (768)
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. (2004) (683)
Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells (2016) (573)
Cognitive Impairments in Early Parkinson's Disease Are Accompanied by Reductions in Activity in Frontostriatal Neural Circuitry (2003) (526)
l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease (2003) (526)
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort (2013) (522)
Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach (2005) (520)
Mild cognitive impairment in Parkinson disease (2010) (443)
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. (2002) (401)
Targeting Huntingtin Expression in Patients with Huntington's Disease. (2019) (393)
Mechanisms of cognitive set flexibility in Parkinson's disease. (2001) (389)
Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis (2012) (387)
Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease (2005) (387)
Microglial activation correlates with severity in Huntington disease (2006) (384)
Microglial activation in presymptomatic Huntington's disease gene carriers. (2005) (382)
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial (2014) (381)
Characterizing mild cognitive impairment in incident Parkinson disease (2014) (354)
The spectrum of nonmotor symptoms in early Parkinson disease (2013) (353)
A cell atlas of human thymic development defines T cell repertoire formation (2020) (322)
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease (2013) (311)
Sleep and circadian rhythm regulation in early Parkinson disease. (2014) (308)
Health‐related quality of life in early Parkinson's disease: The impact of nonmotor symptoms (2014) (307)
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease (2005) (305)
L-DOPA Disrupts Activity in the Nucleus Accumbens during Reversal Learning in Parkinson's Disease (2007) (284)
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity (1998) (280)
A pathophysiological model of freezing of gait in Parkinson's disease. (2009) (279)
A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease (2011) (278)
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease (2017) (278)
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans (2004) (277)
'The clocks that time us'—circadian rhythms in neurodegenerative disorders (2014) (266)
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. (2013) (257)
Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. (2017) (247)
UCHL1 is a Parkinson's disease susceptibility gene. (2004) (247)
Cell-based therapies for Parkinson disease—past insights and future potential (2015) (240)
Neural transplantation for the treatment of Parkinson's disease (2003) (238)
The heterogeneity of idiopathic Parkinson's disease (2002) (220)
Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21 (2010) (215)
The natural history of treated Parkinson's disease in an incident, community based cohort (2011) (215)
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. (2003) (211)
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) (208)
The Time Course of Loss of Dopaminergic Neurons and the Gliotic Reaction Surrounding Grafts of Embryonic Mesencephalon to the Striatum (1996) (206)
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's (2016) (196)
Using executive heterogeneity to explore the nature of working memory deficits in Parkinson’s disease (2003) (196)
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF (2009) (194)
Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition (2008) (187)
Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY (2011) (186)
Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease. (2003) (186)
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. (2006) (185)
The basal ganglia and rule-governed language use: evidence from vascular and degenerative conditions. (2005) (183)
Cerebrovascular and blood–brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology (2015) (183)
Incidence of early-onset dementias in Cambridgeshire, United Kingdom (2008) (181)
Unilateral transplantation of human primary fetal tissue in four patients with Huntington’s disease: NEST-UK safety report ISRCTN no 36485475 (2002) (180)
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD (2005) (179)
Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study (2015) (178)
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE‐PD) (2016) (178)
Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment (2006) (174)
Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines (2016) (174)
Biomarkers and Parkinson's disease. (2004) (171)
The Cambridge Behavioural Inventory revised (2008) (169)
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study (2011) (169)
Hypothalamic involvement in Huntington's disease: an in vivo PET study. (2008) (167)
Catechol O-Methyltransferase val158met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease (2007) (166)
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. (2008) (165)
Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons (2013) (164)
The utility of the Cambridge Behavioural Inventory in neurodegenerative disease (2007) (163)
Decreased hippocampal cell proliferation in R6/1 Huntington's mice (2004) (161)
Mutant huntingtin is present in neuronal grafts in huntington disease patients (2014) (157)
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease (2007) (155)
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease (2009) (149)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial (2011) (146)
New approaches for brain repair—from rescue to reprogramming (2018) (144)
Neural grafting in Parkinson's disease Problems and possibilities. (2010) (143)
Cells of the human intestinal tract mapped across space and time (2021) (141)
Health‐related quality of life in Huntington's disease: Which factors matter most? (2009) (141)
The current clinical management of Huntington's disease (2008) (140)
Immune problems in central nervous system cell therapy (2004) (137)
Abnormalities of Neurogenesis in the R6/2 Mouse Model of Huntington's Disease Are Attributable to the In Vivo Microenvironment (2005) (136)
Cognitive decline and quality of life in incident Parkinson's disease: The role of attention (2016) (136)
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. (2007) (135)
Systematic Review and UK‐Based Study of PARK2 (parkin), PINK1, PARK7 (DJ‐1) and LRRK2 in early‐onset Parkinson's disease (2012) (134)
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease (2008) (134)
Imaging microglial activation in Huntington's disease (2007) (131)
Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment? (2010) (130)
Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study (2014) (129)
Intracellular SERS Nanoprobes For Distinction Of Different Neuronal Cell Types (2013) (128)
The metabolic profile of early Huntington's disease- a combined human and transgenic mouse study (2008) (128)
Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism (2004) (125)
Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease (2016) (123)
Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease? (2016) (123)
Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts (2017) (122)
Targeting impulsivity in Parkinson’s disease using atomoxetine (2014) (119)
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. (2011) (119)
Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life (2014) (118)
Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington’s disease (2008) (115)
Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease (2013) (115)
The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study (2009) (114)
Verbal fluency in Huntington’s disease: a longitudinal analysis of phonemic and semantic clustering and switching (2002) (114)
Neurodegeneration: a failure of neuroregeneration? (2001) (113)
Task-Set Switching Deficits in Early-Stage Huntington's Disease: Implications for Basal Ganglia Function (2003) (112)
The spectrum of cognitive impairment in Lewy body diseases (2014) (112)
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease (2005) (110)
Habitual versus Goal-directed Action Control in Parkinson Disease (2011) (110)
Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease (2019) (107)
The role of tau in the pathological process and clinical expression of Huntington’s disease (2015) (106)
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease (2014) (103)
White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function (2012) (103)
The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders (2013) (103)
Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain (2009) (102)
Defective emotion recognition in early HD is neuropsychologically and anatomically generic (2008) (102)
Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson’s Disease (2015) (102)
Huntington's disease patients have selective problems with insight (2006) (102)
Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression (2018) (99)
Time course of dopamine neuron loss and glial response in the 6‐OHDA striatal mouse model of Parkinson's disease (2014) (99)
UCHL‐1 is not a Parkinson's disease susceptibility gene (2006) (97)
Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts (2019) (97)
Clinical translation of stem cells in neurodegenerative disorders. (2012) (95)
Saccadic latency distributions in Parkinson’s disease and the effects of l-dopa (2006) (94)
Asymptomatic Sleep Abnormalities Are a Common Early Feature in Patients with Huntington’s Disease (2011) (94)
Improving Response Inhibition in Parkinson’s Disease with Atomoxetine (2015) (92)
Cognitive Deficits and Psychosis in Parkinson’s Disease (2006) (92)
Regulation of stem cell therapies under attack in Europe: for whom the bell tolls (2013) (91)
GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro (2003) (90)
Increased thirst and drinking in Huntington's disease and the R6/2 mouse (2008) (89)
Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease (2005) (88)
Neuropeptide Y and its role in CNS disease and repair (2012) (88)
Metabolomic analysis of urine and serum in Parkinson’s disease (2008) (86)
Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease (2005) (86)
Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (85)
Stability of mild cognitive impairment in newly diagnosed Parkinson's disease (2017) (84)
Top–Down Attentional Control in Parkinson's Disease: Salient Considerations (2010) (84)
Cell Therapy in Parkinson’s Disease (2009) (83)
Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study (2018) (83)
Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study (2010) (82)
The clinical heterogeneity of Parkinson's disease and its therapeutic implications (2018) (82)
Emerging Treatment Approaches for Parkinson’s Disease (2018) (82)
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease (2013) (82)
ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update (2021) (82)
Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease (2018) (80)
Cell replacement therapy for Parkinson's disease. (2009) (80)
Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis (2011) (78)
Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson’s disease (2015) (78)
The genetic basis of Parkinson's disease (2002) (77)
Understanding the dopaminergic deficits in Parkinson’s disease: Insights into disease heterogeneity (2009) (77)
Atomoxetine restores the response inhibition network in Parkinson’s disease (2016) (77)
Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon (2004) (77)
REST suppression mediates neural conversion of adult human fibroblasts via microRNA‐dependent and ‐independent pathways (2017) (75)
The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study (2014) (74)
Sleep deficits but no metabolic deficits in premanifest Huntington's disease (2015) (74)
Disease modification and biomarker development in Parkinson disease (2020) (74)
Anti-amyloid Compounds Inhibit α-Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA)* (2014) (74)
Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study (2016) (74)
A Role for Complement in the Rejection of Porcine Ventral Mesencephalic Xenografts in a Rat Model of Parkinson's Disease (2000) (74)
The Potential for Circuit Reconstruction by Expanded Neural Precursor Cells Explored through Porcine Xenografts in a Rat Model of Parkinson's Disease (2002) (73)
Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson’s disease (2016) (73)
Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. (2013) (72)
Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS (2002) (72)
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data (2016) (71)
A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease (2016) (71)
The relation between anger and different forms of disgust: Implications for emotion recognition impairments in Huntington's disease (2010) (70)
Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells (2001) (70)
The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro (2014) (70)
Coping processes and health‐related quality of life in Parkinson's disease (2011) (70)
Review: The spectrum of clinical features seen with alpha synuclein pathology (2016) (69)
Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics. (2016) (69)
Challenges assessing clinical endpoints in early Huntington disease (2010) (69)
Molecular and functional definition of the developing human striatum (2014) (68)
Olfactory abnormalities in Huntington’s disease: Decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients (2007) (66)
Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy (2016) (66)
Neuroendocrine abnormalities in Parkinson's disease (2016) (65)
Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson’s Disease (2020) (64)
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease (2010) (64)
Gold nanoparticles explore cells: cellular uptake and their use as intracellular probes. (2014) (63)
Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016? (2016) (63)
Whole‐brain atrophy as a measure of progression in premanifest and early Huntington's disease (2009) (62)
Exploring causality of the association between smoking and Parkinson’s disease (2018) (62)
The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease. (2006) (62)
Health‐related quality of life in Huntington's disease: A comparison of two generic instruments, SF‐36 and SIP (2004) (62)
Predictors of punding in Parkinson's disease: Results from a questionnaire survey (2007) (62)
Determinants of delayed diagnosis in Parkinson’s disease (2013) (61)
Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease (2009) (60)
Cell therapy in Huntington disease. (2008) (60)
Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). (2017) (60)
Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. (2018) (60)
A comparative study of preparation techniques for improving the viability of striatal grafts using vital stains, in vitro cultures, and in vivo grafts. (1996) (60)
Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease (2006) (59)
The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. (2012) (59)
Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management (2020) (59)
Continuing trials of GDNF in Parkinson's disease (2006) (58)
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome (2012) (58)
Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain (2013) (57)
A roadmap for the Human Developmental Cell Atlas (2021) (57)
Weight changes in Huntington's disease (2006) (56)
Neurotrophic factors as a therapeutic target for Parkinson's disease (2008) (56)
GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte–neuron interactions (2016) (55)
Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity (2011) (55)
Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers (2010) (55)
Dopamine and Huntington’s disease (2015) (54)
Tracking Parkinson’s: Study Design and Baseline Patient Data (2015) (54)
No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. (2006) (54)
Dura mater-associated Creutzfeldt–Jakob disease: experience from surveillance in the UK (2006) (53)
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures (2016) (53)
The use of quantitative oculometry in the assessment of Huntington’s disease (2006) (53)
Genetic risk of Parkinson disease and progression: (2019) (53)
Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease (2017) (53)
Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. (2005) (52)
Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington's disease (2009) (52)
Tumor to normal single cell mRNA comparisons reveal a pan-neuroblastoma cancer cell (2020) (52)
Hippocampal dysfunction defines disease onset in Huntington's disease (2016) (51)
Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease (2016) (51)
Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease (2009) (51)
Patients beware: commercialized stem cell treatments on the web. (2010) (51)
The potential of GDNF as a treatment for Parkinson's disease (2004) (51)
Cellular and molecular aspects of striatal development (2001) (50)
WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis (2019) (49)
A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. (2013) (49)
Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease (2021) (49)
Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease (2016) (49)
The cellular repair of the brain in Parkinson's disease--past, present and future. (2004) (49)
Vascular Parkinsonism: A Review of the Precision and Frequency of the Diagnosis (2001) (48)
Treating Parkinson’s disease in the 21st century: Can stem cell transplantation compete? (2014) (48)
Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study (2019) (48)
Cell-based therapies for Parkinson’s disease (2011) (48)
Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross‐sectional study of iron‐related magnetic resonance imaging susceptibility (2017) (47)
Excessive daytime sleepiness and its risk factors in incident Parkinson's disease (2012) (46)
Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease (2017) (46)
Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells (2011) (45)
Functional integration of neural grafts in Parkinson's disease (1999) (45)
Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned? (2017) (45)
Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study (2016) (45)
G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease (2015) (45)
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop (2020) (45)
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson’s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram (2008) (44)
How vital is sleep in Huntington’s disease? (2010) (44)
Saccadometry: a new tool for evaluating presymptomatic Huntington patients (2007) (44)
Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease (2020) (44)
The use of the Actiwatch–Neurologica® system to objectively assess the involuntary movements and sleep–wake activity in patients with mild–moderate Huntington’s disease (2005) (44)
Successful treatment of stiff man syndrome with intravenous immunoglobulin. (1997) (43)
Huntington’s disease: changes in saccades and hand-tapping over 3 years (2010) (43)
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations (2012) (43)
Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease (2010) (43)
11C‐PE2I and 18F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study (2018) (43)
Foundations of Neurobiology (1998) (42)
Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO). (2014) (42)
Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. (2013) (40)
The Dementias Platform UK (DPUK) Data Portal (2019) (40)
Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation (2011) (39)
Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson’s Disease Using Screening of Multiple Prospective New Treatments (2013) (39)
A novel neuroprotective therapy for Parkinson’s disease using a viral noncoding RNA that protects mitochondrial Complex I activity (2012) (39)
Differences in the Presentation and Progression of Parkinson's Disease by Sex (2020) (39)
Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease (2017) (39)
Current status of clinical trials of neural transplantation in Parkinson's disease. (2012) (39)
Intra‐ and inter‐network functional alterations in Parkinson's disease with mild cognitive impairment (2017) (39)
Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens (2013) (39)
Lewy bodies in Parkinson's disease: Protectors or perpetrators? (2005) (39)
Recent developments in the treatment of Parkinson's Disease (2020) (39)
Gaucher disease and comorbidities: B‐cell malignancy and parkinsonism (2015) (38)
Abnormalities of age-related T cell senescence in Parkinson’s disease (2018) (38)
LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY (2016) (38)
Addenbrooke's Cognitive Examination‐Revised for mild cognitive impairment in Parkinson's disease (2012) (38)
Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease (2003) (37)
The search for a curative cell therapy in Parkinson's disease (2008) (37)
Development and external validation of a prognostic model in newly diagnosed Parkinson disease (2016) (37)
The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease (2018) (37)
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias (2007) (37)
Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals (2015) (37)
A case of late onset sporadic Parkinson’s disease with an A53T mutation in α-synuclein (2005) (37)
Developing stem cell therapies for Parkinson's disease: waiting until the time is right. (2014) (37)
Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. (1997) (37)
The Effect of Truncated Human α-Synuclein (1–120) on Dopaminergic Cells in a Transgenic Mouse Model of Parkinson's Disease (2007) (36)
Hand tapping: A simple, reproducible, objective marker of motor dysfunction in Huntington’s disease (2008) (36)
Identifying sleep disturbances in Huntington’s disease using a simple disease-focused questionnaire (2010) (36)
α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function (2016) (36)
SUBCUTANEOUS APOMORPHINE AS A DIAGNOSTIC TEST FOR DOPAMINERGIC RESPONSIVENESS IN PARKINSONIAN SYNDROMES (1989) (35)
Death of Dopaminergic Neurons in Vitro and in Nigral Grafts: Reevaluating the Role of Caspase Activation (2001) (35)
Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease (2006) (35)
The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease (2010) (35)
Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson’s disease cohort (2006) (35)
Stem cells and neurological disease (2003) (35)
Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson’s disease (2020) (35)
The role of the amygdala during emotional processing in Huntington's disease: From pre-manifest to late stage disease (2015) (35)
Personality affects aspects of health-related quality of life in Parkinson's disease via psychological coping strategies. (2013) (34)
Repairing the brain in Parkinson's disease: Where next? (2002) (34)
The effects of modafinil on mood and cognition in Huntington’s disease (2008) (34)
Longitudinal diffusion tensor imaging changes in early Parkinson’s disease: ICICLE-PD study (2018) (34)
Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. (2019) (34)
Graft-induced dyskinesias in Parkinson's disease: what is it all about? (2010) (34)
Neuroscience at a glance (1999) (34)
Successful treatment of intractable epilepsia partialis continua with multiple subpial transections (1998) (33)
The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. (2007) (33)
Motor complications in Parkinson's disease: 13‐year follow‐up of the CamPaIGN cohort (2019) (33)
Microangiopathy of the brain and retina with hearing loss in a 50 year old woman: extending the spectrum of Susac’s syndrome (1999) (33)
Parkinson's disease and healthy aging: Independent and interacting effects on action selection (2010) (33)
The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? (2014) (33)
Emerging drug therapies in Huntington's disease (2009) (32)
The search for biomarkers in Parkinson’s disease: a critical review (2008) (32)
The Addenbrooke’s Cognitive Examination-Revised accurately detects cognitive decline in Huntington’s disease (2013) (31)
Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease (2020) (31)
Relapsing encephalopathy in a patient with α-methylacyl-CoA racemase deficiency (2007) (31)
Neural Repair, Transplantation and Rehabilitation (1999) (31)
Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell (2021) (31)
The coding and long noncoding single-cell atlas of the developing human fetal striatum (2021) (31)
Parkinson's disease: an autoimmune process. (1988) (31)
Neurotrophic factors as a therapeutic target for Parkinson's disease. (2008) (31)
Mild cognitive impairment and Parkinson's disease--something to remember. (2015) (30)
A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity (2020) (30)
Neural grafting for Parkinson's disease: challenges and prospects (2017) (30)
Stem cells and the treatment of Parkinson's disease (2014) (30)
Neural Tissue Xenotransplantation: What is Needed Prior to Clinical Trials in Parkinson's Disease? (2000) (30)
Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions (2012) (30)
Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study (2017) (30)
Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson’s Disease: The ICICLE-PD Study (2019) (29)
The basal ganglia and pain. (1988) (29)
Prospects for the treatment of Parkinson’s disease using neurotrophic factors (2001) (28)
Neurotransmitter Release and its Modulation (1996) (28)
The incidence of Parkinson's disease in the North-East of England. (2014) (28)
Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis (2018) (27)
Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat (2004) (27)
Quality of life and mild cognitive impairment in early Parkinson's disease: does subtype matter? (2015) (27)
Non-dopamine lesions in Parkinson's disease (2010) (27)
The future of cell-based transplantation therapies for neurodegenerative disorders. (2003) (27)
Tachykinins, Neurotrophism and Neurodegenerative Diseases: A Critical Review on the Possible Role of Tachykinins in the Aetiology of CNS Diseases (1996) (27)
Modern therapeutic approaches in Parkinson's disease (2003) (27)
Tau acts as an independent genetic risk factor in pathologically proven PD (2012) (27)
Variation in Recent Onset Parkinson’s Disease: Implications for Prodromal Detection (2016) (26)
Biomarkers in Huntington's and Parkinson's Disease (2009) (26)
Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature (2016) (26)
Deep Brain Stimulation: Eye Movements Reveal Anomalous Effects of Electrode Placement and Stimulation (2012) (26)
Parkinson disease and growth factors — is GDNF good enough? (2019) (26)
Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion (1997) (26)
Hibernated Human Fetal Striatal Tissue: Successful Transplantation in a Rat Model of Huntington's Disease (2000) (26)
Posterior communicating artery aneurysm presenting with haemorrhage into an arachnoid cyst (1998) (25)
Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency. (2008) (25)
New Therapeutic Approaches to Parkinson’s Disease Including Neural Transplants (2005) (24)
NMDA receptor gene variations as modifiers in Huntington disease: a replication study (2011) (24)
3D‐Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices (2020) (24)
Cerebrospinal Fluid Cytokines and Neurodegeneration‐Associated Proteins in Parkinson's Disease (2020) (24)
Rating Apathy in Huntington’s Disease: Patients and Companions Agree. (2015) (24)
Single cell derived mRNA signals across human kidney tumors (2020) (24)
Portrait of blood-derived extracellular vesicles in patients with Parkinson’s disease (2019) (24)
GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain (2021) (24)
A Comparative Study of Preparation Techniques for Improving the Viability of Nigral Grafts using Vital Stains, in Vitro Cultures, and in Vivo Grafts (1995) (23)
Platelet abnormalities in Huntington’s disease (2018) (23)
Long-Term Hibernation of Human Fetal Striatal Tissue does Not Adversely Affect its Differentiation In Vitro or Graft Survival: Implications for Clinical Trials in Huntington's Disease (2003) (22)
Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson’s disease (2007) (22)
The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards? (2018) (22)
Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease. (2014) (22)
Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients (2016) (22)
Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts (2016) (22)
Novel Nut and Bolt Task Quantifies Motor Deficits in Premanifest and Manifest Huntington’s Disease (2015) (21)
Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14–15 September 2015 (2016) (21)
A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. (2005) (21)
Parkinson's disease – the continuing search for biomarkers (2011) (21)
Learning to be inflexible: Enhanced attentional biases in Parkinson's disease (2016) (21)
Diagnostic potential of saccadometry in progressive supranuclear palsy. (2007) (21)
iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia (2018) (21)
Simple Generation of a High Yield Culture of Induced Neurons from Human Adult Skin Fibroblasts (2018) (21)
Huntington’s disease: diagnosis and management (2021) (21)
Migration and differentiation of transplanted human neural precursor cells (2003) (20)
The Current Status of Neural Grafting in the Treatment of Huntington’s Disease. A Review (2011) (20)
Rate and acceleration of whole‐brain atrophy in premanifest and early Huntington's disease (2010) (20)
A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice (2019) (20)
Early constipation predicts faster dementia onset in Parkinson’s disease (2021) (20)
An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease (2017) (20)
Body composition in premanifest Huntington’s disease reveals lower bone density compared to controls. (2011) (19)
Using Medical Claims Analyses to Understand Interventions for Parkinson Patients (2017) (19)
Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease (2016) (19)
Huntington's disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory (2019) (18)
Staging and Preparation of Human Fetal Striatal Tissue for Neural Transplantation in Huntington's Disease (2003) (18)
Pro‐Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE‐PD (2019) (18)
Animal Models of Parkinson's Disease: Are They Useful or Not? (2020) (18)
Survival of Nigral Grafts within the Striatum of Marmosets with 6-Ohda Lesions Depends Critically on Donor Embryo Age (1997) (18)
How does the brain control its own activity? A new function for the basal ganglia. (1988) (18)
A human fetal lung cell atlas uncovers proximal-distal gradients of differentiation and key regulators of epithelial fates (2022) (18)
Medical Neurosciences (1995) (18)
Parkinson's disease and growth factors - are they the answer? (2009) (18)
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease (2011) (18)
Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease (2021) (18)
A Case of Unilateral Neglect in Huntington’s Disease (2003) (18)
The Treatment of Sleep Dysfunction in Neurodegenerative Disorders (2020) (17)
Normal aging and Parkinson's disease are associated with the functional decline of distinct frontal-striatal circuits (2017) (17)
Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease (2006) (17)
Cell therapies for Parkinson's disease: how far have we come? (2016) (17)
Retrospective Assessment of Movement Disorder Society Criteria for Mild Cognitive Impairment in Parkinson’s Disease (2015) (17)
Predicting clinical diagnosis in Huntington's disease: An imaging polymarker (2018) (17)
The factor structure of the UPDRS as an index of disease progression in Parkinson's disease. (2011) (17)
SCA2 presenting as levodopa‐responsive parkinsonism in a young patient from the United Kingdom: A case report (2004) (17)
Stem cells and neurodegenerative diseases: where is it all going? (2012) (16)
Fetal Porcine Dopaminergic Cell Survival in Vitro and its Relationship to Embryonic Age (1999) (16)
Neurogenesis in diseases of the central nervous system. (2006) (16)
The future of cell therapies in the treatment of Parkinson's disease (2007) (16)
Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease (2014) (16)
Making it personal: the prospects for autologous pluripotent stem cell-derived therapies. (2016) (16)
Huntingtin-lowering strategies for Huntington’s disease (2020) (16)
Mild cognitive impairment in Parkinson's disease: millstone or milestone? (2013) (16)
Established and emerging therapies for Huntington's disease. (2007) (16)
Environmental toxins and Parkinson's disease (1989) (16)
Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide (2020) (15)
Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease (2019) (15)
A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity (2020) (15)
The phosphorylation status of Ascl 1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro (2014) (15)
Systemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson’s disease (2019) (15)
Outcome of cell suspension allografts in a patient with Huntington's disease (2018) (14)
Neuroanatomy and Neuroscience at a Glance (1999) (14)
Dual modulation of neuron‐specific microRNAs and the REST complex promotes functional maturation of human adult induced neurons (2019) (14)
A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. (1995) (14)
PAX6 expression may be protective against dopaminergic cell loss in Parkinson's disease. (2016) (14)
Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD) (2020) (14)
Revisiting the effects of Parkinson's disease and frontal lobe lesions on task switching: the role of rule reconfiguration. (2014) (14)
Implantation of the clinical‐grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid‐lesioned rodent model of Huntington's disease (2020) (14)
Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease? (2015) (14)
Pseudo-neglect in Huntington's disease correlates with decreased angular gyrus density (2004) (14)
Modelling the natural history of Huntington's disease progression (2014) (14)
The human cytomegalovirus non-coding Beta2.7 RNA as a novel therapeutic for Parkinson's disease--Translational research with no translation. (2016) (13)
Pax7 expression in the adult rat superior colliculus following optic nerve injury (2007) (13)
Staging and preparation of human fetal striatal tissue for neural transplantation in Huntington's disease. (2003) (13)
Regenerative Therapies for Parkinson’s Disease: An Update (2018) (13)
Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue (2004) (13)
Modelling of a targeted nanotherapeutic ‘stroma’ to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt–β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson’s disease (2014) (13)
Intra-and InterNetwork Functional Alterations in Parkinson ’ s Disease with Mild Cognitive Impairment (2017) (13)
Random Number Generation in Patients with Symptomatic and Presymptomatic Huntington's Disease (2004) (13)
Migration of cells from primary transplants of allo‐ and xenografted foetal striatal tissue in the adult rat brain (2005) (13)
Loss of FBXO7 results in a Parkinson's‐like dopaminergic degeneration via an RPL23–MDM2–TP53 pathway (2019) (13)
Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson’s Disease Cohort (ICICLE-PD) (2020) (13)
Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. (2003) (12)
A new approach to disease-modifying drug trials in Parkinson's disease. (2013) (12)
Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. (2015) (12)
How often does music and rhythm improve patients’ perception of motor symptoms in Parkinson’s disease? (2013) (12)
Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study (2015) (12)
Platelet-derived extracellular vesicles in Huntington’s disease (2018) (12)
A blueprint for translational regenerative medicine (2020) (12)
Apathy in Huntington’s Disease: A Review of the Current Conceptualization (2018) (12)
Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease (2015) (12)
Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We? (2020) (12)
L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. (2019) (12)
Neural Transplantation in Huntington's Disease: The NEST-UK Donor Tissue Microbiological Screening Program and Review of the Literature1 (2006) (12)
Dynamic and Cell-Specific DACH1 Expression in Human Neocortical and Striatal Development. (2019) (12)
Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease (2006) (11)
Porcine neural xenografts: what are the issues? (2000) (11)
The motor and cognitive features of Parkinson’s disease in patients with concurrent Gaucher disease over 2 years: a case series (2018) (11)
Association Between Toll‐Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease (2019) (11)
Author Correction: Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson’s disease (2017) (11)
Prospects for the treatment of Parkinson’s disease using neural grafts (2000) (11)
Parkinson disease: Defining PD subtypes — a step toward personalized management? (2017) (11)
A case of stiff limb syndrome responsive to plasma exchange (2001) (11)
Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases (2017) (11)
Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson’s disease (2020) (11)
Challenges in assessment (2009) (11)
Transplanted human neural precursor cells migrate widely but show no lesion-specific tropism in the 6-hydroxydopamine rat model of Parkinson's disease. (2006) (10)
Transplanted Human Neural Precursor Cells Migrate Widely but Show no Lesion-Specific Tropism in the 6-Hydroxydopamine Rat Model of Parkinson's Disease (2006) (10)
Quantitative evaluation of the human subventricular zone. (2012) (10)
Central Nervous System Diseases: Innovative Animal Models From Lab to Clinic (2001) (10)
&agr;Gal is widely expressed in embryonic porcine stem cells and neural tissue (2002) (10)
The sleep and circadian problems of Huntington’s disease: when, why and their importance (2020) (10)
The heart in systemic lupus erythematosus. (1989) (10)
Novel targets for Huntington’s disease: future prospects (2016) (10)
A Professional Standard for Informed Consent for Stem Cell Therapies. (2019) (10)
Neurotrophic factors and neural grafts: a growing field (1993) (10)
The Genesis of Neuroscience (2000) (9)
A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinson’s disease (2020) (9)
A genome wide linkage disequilibrium screen in Parkinson’s disease (2005) (9)
The clinical phenotype of juvenile Huntington’s disease (2009) (9)
What is the most promising treatment for Parkinson's disease: genes, cells, growth factors or none of the above? (2012) (9)
Hyperosmotic stress induces cell-dependent aggregation of α-synuclein (2019) (9)
DJ-1 can form β-sheet structured aggregates that co-localize with pathological amyloid deposits (2020) (9)
Non-systemic vasculitic neuropathy resenting with a painful polyradiculopathy: a case report (2000) (9)
The relationship between abnormalities of saccadic and manual response times in Parkinson's disease. (2013) (9)
Comparative epidemiology of incident Parkinson's disease in Cambridgeshire, UK (2016) (9)
Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report. (2018) (9)
Dopamine stimulates epidermal growth factor release from adult neural precursor cells derived from the subventricular zone by a disintegrin and metalloprotease (2011) (9)
Adrenal grafting for Parkinson's disease: a role for substance P. (1989) (9)
Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson’s Disease (2018) (8)
Problems with Social Cognition and Decision-Making in Huntington’s Disease: Why Is it Important? (2021) (8)
SLEEP AND CIRCADIAN RHYTHM REGULATION IN EARLY PARKINSON'S DISEASE (2015) (8)
Cortical and Striatal Reward Processing in Parkinson’s Disease Psychosis (2017) (8)
Stem cell transplantation as an approach to brain repair (2001) (8)
Altered subcortical emotional salience processing differentiates Parkinson’s patients with and without psychotic symptoms (2019) (8)
Categorising Visual Hallucinations in Early Parkinson's Disease. (2018) (8)
Using genome-Wwide complex trait analysis to quantify 'missing heritability' in Parkinson's disease (2012) (8)
Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything? (2012) (8)
Stem cell therapies for Parkinson's disease: are trials just around the corner? (2014) (8)
A novel combinational approach of microstimulation and bioluminescence imaging to study the mechanisms of action of cerebral electrical stimulation in mice (2015) (8)
Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson’s disease (2022) (8)
Role of brain imaging in early parkinsonism (2011) (8)
Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington's Disease. (2019) (8)
Animal models of neurodegenerative diseases. (2009) (8)
Adult neurogenesis is unaffected by a functional knock-out of MHC class I in mice (2010) (8)
Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature. (2006) (7)
Current Pharmacological Management in Juvenile Huntington’s Disease (2012) (7)
Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes (2021) (7)
Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington's disease. (2000) (7)
Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project. (2000) (7)
The hunt for better treatments for Huntington's disease (2019) (7)
Localisation in Clinical Neurology (1997) (7)
Lesions Associated with Cognitive Impairment and Dementia (2010) (7)
Progress in Huntington’s disease: the search for markers of disease onset and progression (2015) (7)
MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. (2021) (7)
Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders (2022) (7)
A simple assessment model to quantifying the dynamic hippocampal neurogenic process in the adult mammalian brain (2016) (7)
Neuroanatomy: 3D-Stereoscopic Atlas of the Human Brain (2000) (7)
Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease (2020) (7)
Dermal fibroblasts from patients with Parkinson’s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations (2017) (6)
New hands at the helm (2011) (6)
Neural stem cell technology as a novel treatment for Parkinson's disease. (2001) (6)
Exogenous melatonin for Parkinson's disease: 'Waking up' to the need for further trials. (2016) (6)
Associations between Lifestyle Factors and Parkinson's Disease in an Urban Sri Lankan Clinic Study. (2017) (6)
The Differential Diagnosis of Parkinson’s Disease (2018) (6)
Evaluation of PLGA Nanoparticles Carrying Leukaemia Inhibitory Factor for Stromal-Like Support of Rat Fetal Dopaminergic Cells (2014) (6)
A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington’s disease (2014) (6)
Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson’s Disease in the ICICLE-PD Cohort (2021) (6)
J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington’s disease, results of the first htt-lowering drug trial (2018) (6)
Neuroscience : an illustrated guide (1991) (6)
Delayed postanoxic encephalopathy and pseudodeficiency of arylsulphatase A (1999) (6)
Spatial structure normalises working memory performance in Parkinson's disease (2017) (6)
Putative cortical dopamine levels affect cortical recruitment during planning☆ (2013) (6)
Dopaminergic modulation of high-level cognition in Parkinson's disease: The role of prefrontal cortex and basal ganglia revealed by PET (2001) (6)
From molecule to clinic and community for neurodegeneration: research to bridge translational gaps. (2012) (6)
The rejection of neural xenotransplants: a role for antibodies. (1999) (6)
Visualising disease progression on multiple variables with vector plots and path plots (2009) (6)
Supplementary Sensorimotor Area (1996) (6)
Current Understanding of the Glial Response to Disorders of the Aging CNS (2012) (5)
Cognitive Deficits in Early Parkinson’s Disease: New Areas of Research (2012) (5)
How common is dementia with Lewy bodies? (2003) (5)
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. (2004) (5)
Neural transplantation therapies for Parkinson's and Huntington's diseases. (2001) (5)
No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson’s disease (2009) (5)
Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. (2017) (5)
MEIS-WNT5A axis regulates development of 4th ventricle choroid plexus (2020) (5)
No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease. (2006) (5)
Cell therapies for neurological disease – from bench to clinic to bench (2005) (5)
Late-onset Huntington’s disease associated with CAG repeat lengths of 30 and 31 (2021) (5)
The neurological assessment of patients in vegetative and minimally conscious states (2005) (5)
No alterations in α‐synuclein gene dosage observed in sporadic Parkinson's disease (2006) (5)
Voices of biotech (2016) (4)
Preparation of Cell Suspensions for Transplantation (2000) (4)
Stem cells and regenerative therapies for Parkinson's disease. (2012) (4)
Combining biomarkers for prognostic modelling of Parkinson’s disease (2022) (4)
Clinical effects of a cation-exchange resin (Zeo-Karb 225). (1951) (4)
A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS (2017) (4)
Reduced expression of dopamine D2 receptors on astrocytes in R6/1 HD mice and HD post-mortem tissue (2021) (4)
A quantitative model of cellular decision making in direct neuronal reprogramming (2020) (4)
Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease. (2018) (4)
Graft outcomes influenced by co‐expression of Pax7 in graft and host tissue (2009) (4)
Can endogenous stem cells be stimulated to repair the degenerating brain? (2004) (4)
CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease (2017) (4)
Cognitive follow up of a small cohort of Huntington’s disease patients over a 5 year period. (2010) (4)
Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. (2020) (4)
Parkinson’s disease and 2009: recent advances (2010) (4)
Sleep, But No Metabolic, Deficits In Pre-Manifest Huntington's Disease (2015) (4)
Parkinson's Disease. What is it? What causes it? And how can it be cured? (2007) (4)
Relapsing encephalopathy in a patient with &agr;-methylacyl-CoA racemase deficiency (2009) (4)
Is There a Future for Neural Transplantation? (2012) (4)
Movement disorders and psychiatry: Five new things. (2015) (4)
Effects of surgical anaesthesia on the viability of nigral grafts in the rat striatum. (1998) (4)
The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of Huntington’s Disease Patients (2020) (4)
J03 The Effect Of Multidisciplinary Rehabilitation On Brain Structure And Cognition In Huntington’s Disease: An Exploratory Study (2014) (4)
Neuroanatomy And Neuroscience At A Glance 4th Ed. (2012) (3)
A selective tachykinin receptor agonist promotes differentiation but not survival of rat chromaffin cells in vitro (2004) (3)
“The eyes have it”. Saccadometry and Parkinson's disease (2009) (3)
Parkinson’s disease laterality: a 11C-PE2I PET imaging study (2020) (3)
Metastatic non-seminomatous germ cell tumour and dermatomyositis. (1990) (3)
Getting to the heart of dementia (2001) (3)
Quantitative variation of free amino acids in the central nervous system of MoMuLV-ts1-infected mice. (1998) (3)
Age-Related Dopamine-Dependent Disorders (1995) (3)
Age-related pathological impairments in induced neurons derived from patients with idiopathic Parkinson’s disease (2021) (3)
Assessing Human Embryonic Stem Cell-Derived Dopaminergic Neuron Progenitor Transplants Using Non-invasive Imaging Techniques (2020) (3)
Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (3)
Prediction of manifest Huntington disease with clinical and imaging measures: A 12-year prospective observational study (2020) (3)
Parkinson's disease: diagnosis and current management (2015) (3)
Negative Motor Phenomena. (Advances in Neurology Vol. 67) (1996) (3)
New approaches for brain repair—from rescue to reprogramming (2018) (3)
Neuroanatomy and Neuroscience at a Glance Ed. 4 (2012) (3)
Immunohistochemical Identification of Rat Adrenal Cortical Tissue in Situ, in Vitro, and in Intracerebral Adrenal Grafts (1993) (3)
The heart in systemic lupus erythematosus: a cause of myocardial infarction in a man of 20 (1989) (3)
The Cerebrospinal Fluid Profile of Cholesterol Metabolites in Parkinson’s Disease and Their Association With Disease State and Clinical Features (2021) (3)
Rapid decline in motor symptoms in HD neural transplant patients prior to surgery (2004) (3)
GFORCE-PD still going strong in 2016 (2017) (3)
GAPDH controls extracellular vesicle biogenesis and enhances therapeutic potential of EVs in silencing the Huntingtin gene in mice via siRNA delivery (2020) (3)
The future challenges in Parkinson’s Disease (2004) (3)
Current Pharmacological Management in Juvenile Huntington's Disease. (2012) (3)
Immune problems in central nervous system cell therapy (2004) (3)
The challenges of administering cell-based therapies to patients with Parkinson’s disease (2013) (3)
Title : Treating Parkinson ' s disease in the 21 st century – can stem cell transplantation compete ? (2013) (3)
Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease (2018) (3)
Cell-based therapies for disorders of the CNS (2005) (3)
In vivo imaging of activated microglia by 11C-PK11195 PET. A biomarker of neuroinflammation in Huntington's disease? (2005) (3)
Genome-wide association study of Parkinson’s disease progression biomarkers in 12 longitudinal patients’ cohorts (2019) (3)
The central clock in patients with Parkinson disease--reply. (2014) (3)
Frequency and profile of mild cognitive impairment in Parkinson's disease: A multicentre meta-analysis of neuropsychological data (2009) (3)
Pseudogenes limit the identification of novel common transcripts generated by their parent genes (2022) (3)
Locus Coeruleus Integrity from 7T MRI Relates to Apathy and Cognition in Parkinson's Disease and Progressive Supranuclear Palsy (2021) (3)
L-dopa responsive parkinsonism secondary to a subdural haematoma (2013) (3)
Body composition in premanifest Huntington's disease reveals lower bone density compared to controls. (2011) (3)
Human Trials of StemCell-Derived Dopamine Neurons for Parkinson ’ s Disease : Dawn of a New Era (2017) (3)
of 23 patients a V ected by the sti V man syndrome : clinical subdivision into sti V trunk ( man ) syndrome , sti V limb syndrome , and progressive encephalomyelitis with rigidity (1998) (2)
Accurate predictive models of Atomextine's and Citalopram's effect on motor inhibition in Parkinson's disease (2014) (2)
Reprogramming Human Adult Fibroblasts into GABAergic Interneurons (2021) (2)
Parkinson's Disease: The Treatment Options (2000) (2)
A-Z of Neurological Practice, Second Edition (2011) (2)
Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease (2020) (2)
Porcine Neural Xenotransplantation: Current Status (2006) (2)
Neurodegenerative disease: Mapping the natural history of Huntington disease (2014) (2)
Neurodegenerative disorders: the Glia way forward (2014) (2)
Bailliere's Clinical Neurology. Genetics In Neurology (1995) (2)
14 - Factors Important in the Survival of Dopamine Neurons in Intracerebral Grafts of Embryonic Substantia Nigra (1994) (2)
Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells (2022) (2)
Distinct sub-cellular autophagy impairments occur independently of protein aggregation in induced neurons from patients with Huntington’s disease (2021) (2)
Stem Derived Dopamine Neurons: Will They Replace DBS as the Leading Neurosurgical Treatment for Parkinson's Disease? (2021) (2)
Regional cerebral blood flow in Alzheimer's disease (1990) (2)
Single-cell transcriptional and functional analysis of dopaminergic neurons in organoid-like cultures derived from human fetal midbrain (2022) (2)
SUSCEPTIBILITY WEIGHTED IMAGING TO DETECT NIGRAL IRON ACCUMULATION IN PARKINSON'S DISEASE (2015) (2)
Poster Presentations (2012) (2)
The A-Z of Neurological Practice: A Guide to Clinical Neurology (2005) (2)
Cell therapies and Parkinson's disease: where next? Interviewed by Emily Culme-Seymour. (2010) (2)
Motor Neuron Disease. Biology and Management (1996) (2)
A human embryonic limb cell atlas resolved in space and time (2023) (2)
Huntington's disease progression measured with serial [11C]-raclopride PET and the UHDRS (2001) (2)
Single cell transcriptional and functional analysis of human dopamine neurons in 3D fetal ventral midbrain organoid like cultures (2020) (2)
Experience and opinions on post-graduate dementia training in the UK : a survey of selected consultant geriatricians (2014) (2)
Journal of Neurology: ready for continued success (2012) (2)
Comprehensive cell atlas of the first-trimester developing human brain (2022) (2)
The long-term safety and ef fi cacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington ’ s disease (2013) (2)
Comprar Neuroanatomy And Neuroscience At A Glance 4th Ed. | Roger Barker | 9780470657683 | Wiley (2012) (1)
NEST-UK safety report ISRCTN no 36485475 tissue in four patients with Huntington's disease: Unilateral transplantation of human primary fetal (2007) (1)
Cholinergic dysfunction in Parkinson’s disease with mild cognitive impairment: a short latency afferent inhibition study (2012) (1)
Transvascular delivery of α-synuclein preformed fibrils, using the RVG9R delivery system, generates α-synuclein pathology in the duodenal myenteric plexus of non-transgenic rats (2021) (1)
Neural transplants for parkinson’s disease: what are the issues? (2006) (1)
Adult neural precursor cells and brain repair (1)
Genetic Neuroimaging Studies of Basal Ganglia Disorders (2016) (1)
Author Correction: GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain (2021) (1)
In memory of Tom Isaacs: The epitomical mover and shaker (2018) (1)
CEREBRAL REORGANIZATION OF FUNCTION AFTER BRAIN DAMAGE.Edited by Harvey S. Levin and Jordan Grafman. 2000. Oxford: Oxford University Press. Price £39.50. Pp. 392. ISBN 0-19512-026-4. (2001) (1)
Study of an FBXO7 patient mutation reveals Fbxo7 and PI31 co-regulate proteasomes and mitochondria (2021) (1)
Biofunctionalised bacterial cellulose scaffold supports the patterning and expansion of human embryonic stem cell-derived dopaminergic progenitor cells (2021) (1)
Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia (2007) (1)
Glucocerebrosidase mutations influence the natural history of PD in a community-based incident cohort (2012) (1)
Cellular mRNA signals in human kidney tumors (2020) (1)
IPSC MODELING OF PSEN1 MUTATION IN ALZHEIMER’S DISEASE WITH CEREBELLAR ATAXIA (2019) (1)
Depression and anxiety in incident Parkinson’s disease (2012) (1)
Parkinson's disease as a preventable pandemic (2020) (1)
B lymphocyte responses in Parkinson’s disease and their possible significance in disease progression (2023) (1)
Faculty Opinions recommendation of Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. (2010) (1)
Current Pharmacological Management in Juvenile Huntington's Disease. (2012) (1)
Blue Books of Practical Neurology Movement Disorders 1 and 2 Reissue (1996) (1)
Motor Activity and Movement Disorders (1996) (1)
The ethical issues of trials of neural grafting in patients with neurodegenerative (2011) (1)
Ef fi cient expansion and dopaminergic differentiation of human fetal ventral midbrain 2 neural stem cells by midbrain morphogens ☆ 3 (2012) (1)
Distinct subcellular autophagy impairments in induced neurons from patients with Huntington's disease (2021) (1)
Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. (2021) (1)
Disease-Modification in Huntington's Disease: Moving Away from a Single-Target Approach. (2019) (1)
F11 Verbal memory in huntington’s disease: a longitudinal study (2016) (1)
131GASTROPARESIS SYMPTOMS IN EARLY PARKINSON'S DISEASE (2014) (1)
Mitochondrial haplogroups and cognitive progression in Parkinson's disease. (2022) (1)
Correction to: Late‑onset Huntington’s disease associated with CAG repeat lengths of 30 and 31 (2021) (1)
NEURAL XENOTRANSPLANTATION: READY FOR THE CLINIC? (2001) (1)
Associations between regional brain atrophy, executive control, and saccadic latency in Parkinson's disease and healthy ageing (2010) (1)
Effects of Surgical Anaesthesia on the Viability of Nigral Grafts in the Rat Striatum (1998) (1)
Deletions at 22q11.2 in idiopathic Parkinson's disease: A combined analysis of GWAS data (2016) (1)
Hunting out the autophagic problem in Huntington disease (2022) (1)
Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts (2022) (1)
The Utility of Breath Analysis in the Diagnosis and Staging of Parkinson's Disease. (2022) (1)
Do different pharmacological treatments have different effects on saccadic eye movement abnormalities in Parkinson's disease? (2009) (1)
Cell Death and Diseases of the Nervous System (2000) (1)
What have open label studies of cell based therapies for Parkinson's disease told us, if anything? (2014) (1)
Working memory ability in Parkinson's disease is associated with the COMT val(108/158)met polymorphism (2004) (1)
GREY MATTER AND CSF AMYLOID IN EARLY NON–DEMENTED PARKINSON'S DISEASE: THE INCIDENCE OF COGNITIVE IMPAIRMENT IN COHORTS WITH LONGITUDINAL EVALUATION IN PARKINSON'S DISEASE (ICICLE–PD) STUDY (2013) (1)
Lessons learnt, and still to learn, in first in human stem cell trials. (2022) (1)
Movement disorders other than Parkinson’s disease (2010) (1)
Exploring the predictors of financial impairment in Huntington’s disease using the Enroll-HD dataset (2022) (1)
Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment (2022) (1)
123 T and B lymphocyte senescence in parkinson’s disease (2019) (1)
Parkinson's disease and spirituality. (2020) (1)
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson’s Disease to the Clinic: The Investigator’s Perspective (2021) (1)
Neurodegenerative disease: Tracking disease progress in Huntington disease (2011) (0)
Faculty Opinions recommendation of TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. (2012) (0)
LONGITUDINAL DIFFUSION TENSOR IMAGING AS A PREDICTOR OF COGNITIVE DOMAINS DECLINE IN EARLY STAGE PARKINSON’S DISEASE: ICICLE-PD STUDY (2017) (0)
Faculty Opinions recommendation of Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. (2010) (0)
Faculty Opinions recommendation of Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. (2012) (0)
Toxin-Induced Models of Neurological Disorders (1995) (0)
Defining Impaired Olfaction In Parkinson’s Disease: A Comparison Of Methods. (P4.046) (2014) (0)
The limbic-circuitry of Huntington's disease (2009) (0)
NUCLEI IN PARKINSON ’ S DISEASE : A CROSS-SECTIONAL STUDY OF IRON-RELATED MRI SUSCEPTIBILITY Running Title : Motor associations of iron accumulation in PD (2018) (0)
Abnormalities of age-related T cell senescence in Parkinson’s disease (2018) (0)
Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: The genetics of behavior and cognition in Parkinson’s disease (2013) (0)
Parkinson's disease and transplants (2007) (0)
Spatial planning ability in early stage Parkinson’s disease patients (ICICLE-PD) (2012) (0)
Faculty Opinions recommendation of Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. (2021) (0)
Selective neurodegeneration generated by intravenous α‐synuclein pre‐formed fibril administration is not associated with endogenous α‐synuclein levels in the rat brain (2022) (0)
Faculty Opinions recommendation of Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. (2020) (0)
The Myeloid Cell Secretome Regulates Zika Flavivirus Infection of Developing and Malignant Human Neural Progenitor Cells (2022) (0)
Faculty Opinions recommendation of Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice. (2010) (0)
Faculty Opinions recommendation of Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. (2016) (0)
Extensive migration of neural cells from primary striatal xenografts (2002) (0)
R. Horowoski, Y. Mizuno, C.W. Olanow, W.H. Poewe, P. Riederer, J.A. Stoessl, M.B.H. Youdim (Editors) Advances in research on neurodegeneration (volume 10) (2004) (0)
Generation of human cerebral organoids with a structured outer subventricular zone (2023) (0)
Link to record in KAR (2013) (0)
Metacognitive insight into cognitive performance in Huntington’s disease gene carriers (2022) (0)
A touchscreen motivation assessment evaluated in Huntington ’ s disease patients and R 6 / 1 model mice Journal Item (2019) (0)
H54 Investigation of the effects of dopamine antagonist medication on cognition in huntington’s disease (2018) (0)
PO088 Nigral iron susceptibility in parkinson’s disease: a longitudinal study (2017) (0)
Faculty Opinions recommendation of Emerging therapies in Parkinson disease - repurposed drugs and new approaches. (2020) (0)
Clinical and Cognitive Correlates of Brain Inflammation in Parkinson Disease: A PET Study (S33.002) (2013) (0)
3.206 A NOVEL NEUROPROTECTIVE THERAPY FOR PARKINSON'S DISEASE USING A VIRAL NON-CODING RNA THAT PROTECTS MITOCHONDRIAL COMPLEX I ACTIVITY (2012) (0)
Elevated homocysteine levels and cognitive dysfunction in an incident cohort of non-demented Parkinson’s disease patients. (2012) (0)
REMOVED: Huntington's disease – Abnormalities of hippocampal neurogenesis and proliferation in the R6/1 mouse (2015) (0)
Pattern Separation A Functional Role for Adult Hippocampal Neurogenesis in Spatial (2014) (0)
Increased serotonin-to-dopamine transporter ratios in Parkinson disease dyskinesias: a longitudinal study (2016) (0)
123 In vivo evidence of COMT val158met functional polymorphism modulates different levels of dopamine turnover in Parkinson's disease: an 18F-dopa PET study (2012) (0)
24 th Annual Meeting of The Network of European CNS Transplantation and Restoration (2014) (0)
Thank you Jan van Gijn (2013) (0)
Clinical Neurology-Parkinsonism. (1998) (0)
Advances in Behavioural Biology: Volume 43. Neurotransmitters in the human brain (1996) (0)
Edinburgh Research Explorer Targeting Huntingtin Expression in Patients with Huntington’s Disease (2019) (0)
THE ROLE OF TAU IN HUNTINGTON'S DISEASE (2017) (0)
Microfluidic Neural Devices: 3D‐Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices (Adv. Sci. 16/2020) (2020) (0)
Vaccination for Alzheimer ’ s disease (2003) (0)
Corrigendum to "DJ-1 can form β-sheet structured aggregates that co-localize with pathological amyloid deposits". Neurobiology of Disease 134 (2020) 104629 (2020) (0)
Correction to: The Treatment of Sleep Dysfunction in Neurodegenerative Disorders (2020) (0)
LONGITUDINAL DIFFUSION TENSOR IMAGING AS A PREDICTOR OF COGNITIVE DOMAIN DECLINE IN EARLY-STAGE PARKINSON’S DISEASE: ICICLE-PD STUDY (2017) (0)
DEV106377 2216..2224 (2014) (0)
F07 Expanding the response scale of the uhdrs total functional assessment: a pilot study (2010) (0)
Citalopram enhances action inhibition systems in Parkinson's disease (2013) (0)
GENE AND CELL THERAPIES FOR PARKINSON'S DISEASE - WHERE IS IT ALL GOING? (2010) (0)
Diagnosis and Management of Parkinson’s Disease (1999) (0)
J09 When do voice changes affect quality of life in Huntington's disease? (2010) (0)
Faculty Opinions recommendation of Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. (2020) (0)
The neurology community mourns the passing of Dr. John F. Kurtzke (2016) (0)
P1.128 The natural history of treated PD: speech, gait and posture symptoms are a sensitive index of disease progression (2009) (0)
Prevalence of mutations in Parkin, PINK1, and DJ-1 in early onset Parkinson's Disease - a community based and regional study [Conference Abstract] (2010) (0)
Author Correction: Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson’s disease (2017) (0)
2.026 INCREASED MICROGLIAL ACTIVATION AND AMYLOID DEPOSITION IN PARKINSON'S DISEASE SUBJECTS AT HIGH RISK OF DEMENTIA: A PET STUDY (2012) (0)
Mitochondrial DNA variation and Parkinson disease (2004) (0)
Huntington's disease: an overview (2007) (0)
Serum neurofilament light as a biomarker for prognosis in patients with newly diagnosed Parkinson disease (2021) (0)
Faculty of 1000 evaluation for Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging. (2013) (0)
Levodopa responsiveness in Parkinson's disease is significantly impaired in those with diabetes and increased vascular risk (2017) (0)
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease. (2023) (0)
EFFECTS OF VASCULAR COMORBIDITY IN PARKINSON'S DISEASE (2016) (0)
SARM1 detection in oligodendrocytes but not Schwann cells though sarm1/Sarm1 deletion does not perturb CNS nor PNS myelination in zebrafish and mice (2022) (0)
Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson’s disease (2017) (0)
Editorial (2014) (0)
TRACKING PARKINSON'S (THE PROBAND STUDY)–INTERIM REPORT FROM THE FIRST 1000 CASES (2013) (0)
Multimodal imaging assessment of nigrostriatal pathway in Parkinson's disease using 11C-PE2I PET and neuromelanin-sensitive MR (2016) (0)
I21 Studying the effect of cariprazine in induced neurons directly reprogrammed from Huntington’s disease patient’s fibroblasts (2022) (0)
The limbic-circuitry of Huntington's disease: A combined neuroimaging approach (2009) (0)
WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis (2019) (0)
Cyclic Amplification ( PMCA )-Synuclein Aggregation Induced by Protein α Anti-amyloid Compounds Inhibit Neurobiology : (2014) (0)
Faculty Opinions recommendation of Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. (2019) (0)
Contributors to Volume 21 (1994) (0)
Principal component discriminant analysis of mild cognitive impairment in Parkinson’s disease reveals early functional changes in the resting state (2016) (0)
Cellular and Molecular Landscape of 3D Human Organoid Models (2020) (0)
Title: SLEEP, BUT NO METABOLIC, DEFICITS IN PRE-MANIFEST HUNTINGTON'S DISEASE (2015) (0)
Early constipation predicts faster dementia onset in Parkinson’s disease (2021) (0)
The need for a standard for informed consent for collection of human fetal material (2022) (0)
SARM1 detection in myelinating glia: sarm1/Sarm1 is dispensable for PNS and CNS myelination in zebrafish and mice (2023) (0)
Faculty Opinions recommendation of Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. (2011) (0)
Contents Vol. 15, 2015 (2015) (0)
Inefficiency of fronto-parietal networks in incident Parkinson’s disease (2012) (0)
Edinburgh Research Explorer Genetic risk of Parkinson disease and progression: (0)
Incidence of dementia and factors predicting cognitive decline in Parkinson's disease (2006) (0)
MOTORNEURON DISEASE: VEGF treatment of ALS (2005) (0)
Neural Transplantation for the Treatment of Huntington’s Disease (2010) (0)
A02 Natural History In Animal Models of HD; HD Recapitulation? (2014) (0)
The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson’s disease (2021) (0)
The Molecular and Genetic Basis of Neurological Disease. (1998) (0)
Anunusual cause forapainful diplopia (1997) (0)
Hyperosmotic stress induces cell-dependent aggregation of α-synuclein (2019) (0)
S.11.03 Can cells repair the brain in Parkinson's disease? (2006) (0)
Sleep-related Disturbances in PD Occurring During Daytime Excessive Daytime Sleepiness (2010) (0)
Faculty Opinions recommendation of Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy. (2020) (0)
The Basal Ganglia V Advances in Behavioural Biology Volume 47. (1997) (0)
Innate immunity and neurodegenerative disorders (2014) (0)
Cognitive follow up of a small cohort of Huntington's disease patients over a 5 year period. (2010) (0)
Faculty Opinions recommendation of Transdifferentiation of human adult peripheral blood T cells into neurons. (2018) (0)
Using medical claims analyses to understand non-pharmacological interventions for Parkinson patients (2018) (0)
Title: Disease-Modification in Huntington’s Disease: Moving Away from a Single-Target Approach Authors: (2019) (0)
Parkinson’s disease over the last 20 years – new concepts and developments (2020) (0)
Faculty Opinions recommendation of Distinct α-synuclein strains differentially promote tau inclusions in neurons. (2013) (0)
367. A Dopamine Gene Therapy for Advanced PD: 4 Years Phase I/II Clinical Update (2016) (0)
The impact of motor and non-motor symptoms upon health-related quality of life in early Parkinson's disease: the incidence of cognitive impairment in cohorts with longitudinal evaluation: Parkinson's Disease (ICICLE-PD) Study (2013) (0)
The Basal Ganglia IV. New Ideas and Data on Structure and Function (1995) (0)
Biofunctionalised bacterial cellulose scaffold supports the patterning and expansion of human embryonic stem cell-derived dopaminergic progenitor cells (2021) (0)
Fulfillment of International Parkinson's and Movement Disorder Society clinical diagnostic criteria for Parkinson's disease in a large cohort study of recent onset cases. (2017) (0)
F13 Assessment of the performance of a modified motor scale as applied to juvenile onset huntington’s disease (2018) (0)
Biology: Brain and Behaviour—The Senses and Communication (1999) (0)
Divergence of cognitive prognosis and susceptibility variants in Parkinson's disease (2021) (0)
Restorative cell and gene therapies for Parkinson's disease. (2023) (0)
Assessing longitudinal iron deposition in deep grey matter nuclei with high-pass filtered phase MR Imaging in Parkinson's disease (2017) (0)
The Treatment of Sleep Dysfunction in Neurodegenerative Disorders (2020) (0)
Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] (2022) (0)
L24 A Proposal For The Assessment Of Fitness To Drive In Patients With Huntington’s Disease (2014) (0)
Editorial Board (2009) (0)
EXPLORING THE ISSUE OF SWALLOWING IN HUNTINGTON'S DISEASE (2010) (0)
Faculty Opinions recommendation of Podiatry interventions to prevent falls in older people: a systematic review and meta-analysis. (2019) (0)
Stem cell application in neurorehabilitation (2015) (0)
Lesions Associated with Eye Movements (2010) (0)
1154 The utility of the Addenbrooke's Cognitive Examination-Revised (ACE-R) in Parkinson's disease (2012) (0)
hL1 retrotransposons drive human neuronal transcriptome complexity and functional diversification (2023) (0)
Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease (2017) (0)
Motor Associations Of Iron Deposition In Patients With Parkinson’s Disease (P6.065) (2015) (0)
Clinical Disorders of Balance, Posture and Gait (1997) (0)
A genome-wide linkage dysequilibrium screen for Parkinson's disease (2002) (0)
Book Reviews (2004) (0)
Brain Regional Identity and Cell Type Specificity Landscape of Human Cortical Organoid Models (2022) (0)
II.1 Cognitive dysfunction in early Parkinson's Disease (2006) (0)
Faculty Opinions recommendation of Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. (2020) (0)
F8 Hippocampal abnormalities in premanifest and early stage huntington’s disease (2016) (0)
Imaging nigrostriatal circuitry with 11C-PE2I PET and Neuromelanin-sensitive MR in Parkinson’s disease (2016) (0)
miRNA and ASO – The initial approach to treating genetic diseases in a new way (2012) (0)
Faculty Opinions recommendation of Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress. (2020) (0)
Current Pharmacological Management in Juvenile (2012) (0)
Brain repair: Do it yourself (2006) (0)
Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson’s (2023) (0)
The prion hypothesis of neurodegenerative disease spreads (2011) (0)
Comprar A-Z of Neurological Practice | Larner, A.J. | 9781848829930 | Springer (2011) (0)
Erratum: A-Z of Neurological Practice (2011) (0)
The Origins of the Protein Spread in Parkinson's Disease (2021) (0)
P1.218 Safety, tolerability and pharmacokinetics of Cogane™ (PYM50028) studied over 28 days in healthy subjects and patients with mild-moderate Parkinson's disease (2009) (0)
Using stem cells to repair the Parkinsonian brain:will it work? (2005) (0)
Genome-wide determinants of mortality and clinical progression in Parkinson's disease (2022) (0)
BrainInfo: http://braininfo.rprc.washington.edu (2004) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
F35 The contribution of motor speed to performance on cognitive processing tasks in huntington’s disease (2018) (0)
6th edn Sir Roger Bannister (1985) (0)
3D‐Printed Soft Lithography for Complex Compartmentalized Microfluidic Neural Devices (2021) (0)
The annotation and function of the Parkinson’s and Gaucher disease-linked gene GBA1 has been concealed by its protein-coding pseudogene GBAP1 (2023) (0)
Regenerative Therapies for Parkinson’s Disease: An Update (2018) (0)
The Microglial Secretome Regulates Flavivirus Infection of Developing and Malignant Human Neural Stem Cells (2022) (0)
Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease (2018) (0)
F27 Factors that influence financial vulnerability in huntington’s disease (2018) (0)
Title: MOTOR ASSOCIATIONS OF IRON ACCUMULATION IN DEEP GREY MATTER NUCLEI IN PARKINSON’S DISEASE: A CROSS-SECTIONAL STUDY OF IRON-RELATED MRI SUSCEPTIBILITY Running Title: Motor associations of iron accumulation in PD AUTHORS: (2017) (0)
A retrospective assessment of MDS criteria for mild cognitive impairment in Parkinson’s disease. (2015) (0)
GREY MATTER CORRELATIONS OF COGNITIVE IMPAIRMENT IN EARLY PARKINSON'S DISEASE: THE INCIDENCE OF COGNITIVE IMPAIRMENT IN COHORTS WITH LONGITUDINAL EVALUATION–PARKINSON'S DISEASE (ICICLE–PD) STUDY (2013) (0)
Huntington's disease - Abnormalities of hippocampal neurogenesis and proliferation in the R6/1 mouse. (2015) (0)
Faculty Opinions recommendation of Pericyte loss influences Alzheimer-like neurodegeneration in mice. (2013) (0)
Widespread migration of human expanded neural precursors in the 6-OHDA model of Parkinson's disease. (2002) (0)
FAMILY HISTORY IN YOUNG ONSET PARKINSON'S DISEASE (2013) (0)
Etiology of Parkinson's Disease (1996) (0)
Current Concepts in Parkinson's Disease Research (1995) (0)
An unusual cause for a painful diplopia. (1998) (0)
Functional Neuroscience by Oswald Steward, Springer-Verlag, 2000. DM 106 (xv 1 549 pages) ISBN 0 387 98543 3 (2000) (0)
Faculty Opinions recommendation of Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. (2020) (0)
Serotonin-to-dopamine transporter ratios in Parkinson's dyskinesias: The longitudinal study (2017) (0)
Telomere length and cognitive impairment in early Parkinson's disease (2013) (0)
Exploring Genetic Influences On Variation In The Phenotypic Expression Of Parkinson’s Disease. (P2.029) (2014) (0)
Neural transplantation: an introduction (2000) (0)
A fourth ventricular papilloma presenting with transient autonomic failure (1999) (0)
Section II: Cognitive Dysfunction and Dementia II.1 Cognitive dysfunction in early Parkinson’s Disease (2006) (0)
Anti-cholinergic load: Is there a cognitive cost in early Parkinson’s disease? (2012) (0)
J01 Improving Prediction Of Huntington Disease Onset With Clinical And Imaging Measures: A 10-year Preopective Study Of Converters (2014) (0)
Faculty Opinions recommendation of PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically. (2015) (0)
Faculty Opinions recommendation of Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. (2020) (0)
Associations between regional brain atrophy, executive control, and saccadic latency in Parkinson's disease and healthy aging (2010) (0)
The CamPaIGN study of incident Parkinson's disease: Natural history over the first 10 years (2012) (0)
Dopamine and Huntington's (2015) (0)
THE EFFECT OF ATOMOXETINE ON IMPULSIVITY IN PARKINSON'S DISEASE (2011) (0)
The Comprehensive Management of Parkinson's Disease (1996) (0)
A Comparative Study of Preparation Techniques for Improving the Viability of Striatal Grafts Using Vital Stains, in Vitro Cultures, and in Vivo Grafts (1996) (0)
What ’ s new in the treatment of Huntington ’ s Disease ? (0)
Motor heterogeneity in Parkinson's disease: An epidemiological and genetic investigation (2005) (0)
Diabetes and Small Vessel Cerebrovascular Disease Influence Motor and Cognitive Features in Early Parkinson’s Disease (S19.006) (2016) (0)
Correction: MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. (2022) (0)
Challenges in the clinical advancement of cell therapies for Parkinson’s disease (2023) (0)
Faculty Opinions recommendation of Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. (2013) (0)
107 Longitudinal evaluation of excessive daytime sleepiness and its risk factors in Parkinson's disease (2012) (0)
Hallucinations in Parkinson’s Disease (2016) (0)
11C-PE2I and 18F-DOPA PET imaging for assessing the severity and rate of progression in Parkinson's disease: The longitudinal study (2017) (0)
Tackling the Ethical Challenges Associated with Premature Delivery of Stem Cell-Based Therapies: Report of a Focus Session at the ISSCR 2018 Annual Meeting (2018) (0)
Detection of antibodies against the huntingtin protein in human plasma (2023) (0)
Emergingdrugtherapiesin Huntington'sdisease (2009) (0)
Nigral iron susceptibility in Parkinson's disease (PD) (2015) (0)
Apathy in incident Parkinson’s disease (2012) (0)
Faculty Opinions recommendation of Adenosine receptor signaling modulates permeability of the blood-brain barrier. (2012) (0)
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. (1992) (0)
Therapy of Parkinson's Disease. Second Edition Revised and Expanded (1995) (0)
Disease 6 The Differential Diagnosis of Parkinson ’ s Disease (2018) (0)
Metacognitive insight into cognitive performance in pre and early-stage Huntington's disease (2021) (0)
Advances in Research on Neurodegeneration (2000) (0)
Longitudinal comparison of 11C-PE2I and 18F-DOPA pet for assessing severity and rate of disease progression in patients with Parkinson’s disease (2017) (0)
Table 1, The clinical diagnostic criteria for Parkinson’s disease, based on the Movement Disorder Society guidelines (2018) (0)
Degenerative Neurological and Neuromuscular Disease Stem cells and regenerative therapies for Parkinson ’ s disease (2012) (0)
Autoimmune Mechanisms in Parkinson's Disease: A Reply (1989) (0)
The pathophysiological and prognostic heterogeneity of mild cognitive impairment in Parkinson’s disease (2015) (0)
F19 Exploring the issue of swallowing in huntington's disease (2010) (0)
Informed Consent for Stem Cell-Based Interventions-Reply. (2020) (0)
2.039 LONGITUDINAL PET STUDIES OF MICROGLIAL ACTIVATION IN HUNTINGTON'S DISEASE (2012) (0)
O.059 Are growth factors the answer in Parkinson's disease? (2009) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
Reviewer Acknowledgment (2012) (0)
The future of stem cells in neurodegenerative disorders of the central nervous system (2012) (0)
Can patient-specific transdifferentiated neuronal cells help us understand the cellular pathology of Parkinson’s disease? (2013) (0)
Figure 1, [A case of Parkinson’s disease...]. (2018) (0)
Faculty Opinions recommendation of Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. (2014) (0)
Parkinson’s Disease, Religious Belief and Spirituality (2019) (0)
Supplementary Material for: Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study (2017) (0)
Characterisation Of Cognitive Decline Over 5 Years In An Incident Parkinson’s Disease Cohort: Results From The CamPaIGN Study (P6.061) (2015) (0)
Moving Closer to Cell Therapies for PD (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roger Alistair Barker?

Roger Alistair Barker is affiliated with the following schools:

Roger Alistair Barker's Academic­Influence.com Rankings

Roger Alistair Barker's Degrees

Why Is Roger Alistair Barker Influential?

Roger Alistair Barker's Published Works

Published Works

What Schools Are Affiliated With Roger Alistair Barker?

Roger Alistair Barker's AcademicInfluence.com Rankings